Stockreport

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF - Subcutaneous VRDN-003 pivotal program in thyroid eye disease expected to start mid-year 2024 pending regulatory authority alignment, as previously shared - - Fc rec [Read more]